EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploratory, Randomized, Dose-Response Study of the Anti-PD-L1 Antibody HFC-L1/c4G12 in Dogs with Pulmonary Metastatic Oral Malignant Melanoma

Kenji Hosoya, Sangho Kim, Ryohei Kinoshita, Naoya Maekawa, Satoru Konnai, Satoshi Takagi iD, Michihito Tagawa, Yumiko Kagawa, Tatsuya Deguchi, Ryo Owaki, Yurika Tachibana, Madoka Yokokawa und 14 weitere

Veterinary Sciences · 02.09.2025 · 12 (9) · 850

DOI: 10.3390/vetsci12090850 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary Sciences, online erschienen am 02.09.2025. Verfasst von Kenji Hosoya und 25 weiteren Autor:innen. Beteiligte Einrichtung: Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0819, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral malignant melanoma (OMM) is a highly aggressive malignancy in dogs. The development of effective systemic therapies is urgently required to improve the treatment of canine OMM. Immunotherapy using immune checkpoint inhibitors (ICIs) has been investigated in canines following their dramatic success in human cancer treatment; however, there is still a need for extensive veterinary clinical studies to clarify and optimize their clinical benefits. Among the ICIs under development for canine cancer immunotherapy, c4G12 (HFC-L1), a canine chimeric anti-PD-L1 antibody, has shown promising efficacy in dogs with pulmonary metastatic OMM in previous clinical studies. However, the optimal dose of HFC-L1/c4G12 has not yet been determined. To explore the dose–response relationship of HFC-L1, a multicenter, randomized clinical study was conducted using three different doses (2, 5, or 10 mg/kg via intravenous infusion every 2 weeks) to treat dogs with pulmonary metastatic OMM (n = 8–9 per group). The safety profiles were similar among the dose groups, and numerically longer median overall survival was achieved in the higher dose groups (5 and 10 mg/kg) than in the 2 mg/kg group. Although the study was exploratory in nature with a small sample size, 5–10 mg/kg should be considered the preferred dose in future clinical studies using HFC-L1.

Schlagwörter

Stichwörter der Autor:innen

canine tumorimmune checkpoint inhibitorimmunotherapymalignant melanomaprogrammed death ligand 1 (PD-L1)

Autor:innen und Institutionen

  • Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0819, Japan.
  • Cancer Research Unit, One Health Research Center, Hokkaido University, Sapporo 060-0818, Japan.
  • Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan.
  • Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan.
  • Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo 001-0021, Japan.
  • Veterinary Research Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan.

ORCID-Profile: Satoshi Takagi, Hiroto Takeuchi, Ayano Kudo, Shintaro Kamo, Yukinari Kato, Yasuhiko Suzuki, Tomohiro Okagawa, Shiro Murata, Kazuhiko Ohashi

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Hosoya, K., Kim, S., Kinoshita, R., Maekawa, N., Konnai, S., Takagi, S., Tagawa, M., Kagawa, Y., Deguchi, T., Owaki, R., Tachibana, Y., Yokokawa, M., Takeuchi, H., Nakamura, H., Yamauchi, A., Kudo, A., Kamo, S., Kato, Y., Kanazawa, S., …, & Ohashi, K. (2025). Exploratory, Randomized, Dose-Response Study of the Anti-PD-L1 Antibody HFC-L1/c4G12 in Dogs with Pulmonary Metastatic Oral Malignant Melanoma. Veterinary Sciences, 12(9), 850. https://doi.org/10.3390/vetsci12090850

Vancouver

Hosoya K, Kim S, Kinoshita R, Maekawa N, Konnai S, Takagi S, et al. Exploratory, Randomized, Dose-Response Study of the Anti-PD-L1 Antibody HFC-L1/c4G12 in Dogs with Pulmonary Metastatic Oral Malignant Melanoma. Veterinary Sciences. 2025;12(9):850. doi:10.3390/vetsci12090850

BibTeX
@article{Hosoya2025,
  author = {Hosoya, Kenji and Kim, Sangho and Kinoshita, Ryohei and Maekawa, Naoya and Konnai, Satoru and Takagi, Satoshi and Tagawa, Michihito and Kagawa, Yumiko and Deguchi, Tatsuya and Owaki, Ryo and Tachibana, Yurika and Yokokawa, Madoka and Takeuchi, Hiroto and Nakamura, Hayato and Yamauchi, Akinori and Kudo, Ayano and Kamo, Shintaro and Kato, Yukinari and Kanazawa, Shigeki and Abe, Tomoyuki and Furuta, Takuya and Yamamoto, Keiichi and Suzuki, Yasuhiko and Okagawa, Tomohiro and Murata, Shiro and Ohashi, Kazuhiko},
  title = {Exploratory, Randomized, Dose-Response Study of the Anti-PD-L1 Antibody HFC-L1/c4G12 in Dogs with Pulmonary Metastatic Oral Malignant Melanoma},
  journal = {Veterinary Sciences},
  year = {2025},
  volume = {12},
  number = {9},
  pages = {850},
  doi = {10.3390/vetsci12090850}
}
Kostenlos starten →